SCHEMBL1019638

SCHEMBL1019638

CC(CNS(=O)(=O)c1cccs1)Nc1nc(Cc2ccccc2F)ns1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
RAB9A P51151 2/20 0.38
GAA P10253 1/20 0.38
CYP2D6 P10635 1/20 0.38
TP53 P04637 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021482 0.90 TP53 (0.39) HPGDL3MBTL1CYP2C9CYP2C19RAB9A
SCHEMBL1020985 0.87 ALDH1A1 (0.42) ALDH1A1HPGDL3MBTL1GAATP53
SCHEMBL1021327 0.86 CYP2C9 (0.40) ALDH1A1HPGDCYP2C9CYP2C19CYP2D6
SCHEMBL1020254 0.86 CYP2C9 (0.40) HPGDCYP2C9CYP2C19CYP2D6TP53
SCHEMBL1021126 0.84 LMNA (0.42) ALDH1A1HPGDCYP2C9CYP2C19RAB9A
SCHEMBL1019643 0.83 ALDH1A1 (0.36) ALDH1A1HPGDCYP2C9CYP2C19CYP2D6
SCHEMBL1020255 0.83 HTT (0.42) ALDH1A1HPGDCYP2C9CYP2C19RAB9A
SCHEMBL1019529 0.82 CYP2D6 (0.49) ALDH1A1HPGDL3MBTL1CYP2C9CYP2C19
SCHEMBL1018353 0.82 ALDH1A1 (0.40) ALDH1A1L3MBTL1TP53LMNAKMT2A
SCHEMBL1020710 0.82 MAPT (0.41) HPGDCYP2C9CYP2C19CYP2D6TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP ALDH1A1 608/4885HPGD 271/4885L3MBTL1 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.